Exact Sciences stock holds steady as its cancer tests stay central
Published on 07/11/2026 at 10:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exact Sciences (ISIN US30063P1057) remains centered on cancer screening and molecular diagnostics, with its business built around tests that aim to detect disease earlier and guide treatment decisions.
Business focus
The company is known for Cologuard, its noninvasive colorectal cancer screening test, and for a broader oncology portfolio that includes laboratory-developed and diagnostic offerings.
That mix gives Exact Sciences a profile that is more clinical and reimbursement-driven than a typical health care name, so changes in adoption, payer access and procedure volumes tend to matter more than broad market sentiment.
US market anchor
Exact Sciences is a US-listed company, and its shares trade on Nasdaq under the ticker EXAS.
For US investors, that keeps attention on regulatory, commercial and earnings-driven updates rather than on commodity-style macro swings.
Cologuard franchise
Cologuard remains the company's best-known product and the clearest representative of its consumer-facing diagnostics model.
Its scale makes the screening business the key reference point when investors assess the durability of Exact Sciences' revenue base.
Stock context
Exact Sciences stock is tied to execution in a business where recurring screening demand and reimbursement trends matter more than day-to-day market noise.
As of July 11, 2026, 8:00 a.m. UTC, the company is valued by the market through its Nasdaq listing rather than a commodity benchmark or index-style rerating.
Exact Sciences fact box
- Company: Exact Sciences Corp.
- ISIN: US30063P1057
- Ticker: EXAS
- Exchange: Nasdaq
- Sector / Industry: Health Care / Diagnostics & Research
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
